Biodistribution, pharmacokinetics and imaging of 131I-labelled OC125 in ovarian cancer. 1988

H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
Department of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA.

Fifteen patients with or suspected of having ovarian carcinoma were injected intravenously (i.v.) or intraperitoneally (i.p.) with 131I-labelled OC125 F(ab')2. Radioimmunoscintigraphy after i.v. injection revealed 50% of the tumor sites. After i.p. injection all tumor sites were visualized, except in one case in which the antibody remained loculated because of adhesions. One patient with endometrial cancer showed no specific uptake of the antibody after i.p. injection. The serum half-life of the radiolabelled antibody after i.v. injection was 30 hr. After i.p. injection there was a slow appearance of radiolabelled antibody in the blood with a maximum level of 1.4% dose per liter at 24 hr after injection. Urinary excretion of the radiolabel was the same for both routes of administration, with 50% of the dose excreted in approximately 48 hr. Tumor uptake was slightly higher after i.p. injection. Liver and bone marrow uptake after i.p. injection were one-half of the uptake after i.v. injection.

UI MeSH Term Description Entries
D007457 Iodine Radioisotopes Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes. Radioisotopes, Iodine
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011877 Radionuclide Imaging The production of an image obtained by cameras that detect the radioactive emissions of an injected radionuclide as it has distributed differentially throughout tissues in the body. The image obtained from a moving detector is called a scan, while the image obtained from a stationary camera device is called a scintiphotograph. Gamma Camera Imaging,Radioisotope Scanning,Scanning, Radioisotope,Scintigraphy,Scintiphotography,Imaging, Gamma Camera,Imaging, Radionuclide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D014018 Tissue Distribution Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios. Distribution, Tissue,Distributions, Tissue,Tissue Distributions
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens

Related Publications

H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
May 1996, European journal of nuclear medicine,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
March 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
March 1990, Zhonghua fu chan ke za zhi,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
January 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
August 1989, Nuclear medicine communications,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
September 1994, British journal of cancer,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
February 1996, Drug metabolism and disposition: the biological fate of chemicals,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
May 1992, British journal of cancer,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
October 1992, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology,
H J Haisma, and K R Moseley, and A I Battaile, and T C Griffiths, and V R Zurawski, and R C Knapp
May 1993, Clinical chemistry,
Copied contents to your clipboard!